作者
Carmine Rossi, Zahid A Butt, Stanley Wong, Jane A Buxton, Nazrul Islam, Amanda Yu, Maryam Darvishian, Mark Gilbert, Jason Wong, Nuria Chapinal, Mawuena Binka, Maria Alvarez, Mark W Tyndall, Mel Krajden, Naveed Z Janjua, The BC Hepatitis Testers Cohort Team
发表日期
2018/11/1
期刊
Journal of hepatology
卷号
69
期号
5
页码范围
1007-1014
出版商
Elsevier
简介
Background & Aims
Direct-acting antiviral therapies (DAA) are an important tool for hepatitis C virus (HCV) elimination. However, reinfection among people who inject drugs (PWID) may hamper elimination targets. Therefore, we estimated HCV reinfection rates among DAA-treated individuals, including PWID.
Methods
We analyzed data from the British Columbia Hepatitis Testers Cohort which included ∼1.7 million individuals screened for HCV in British Columbia, Canada. We followed HCV-infected individuals treated with DAAs who achieved a sustained virologic response (SVR) and had ≥1 subsequent HCV RNA measurement to April 22nd, 2018. Reinfection was defined as a positive RNA measurement after SVR. PWID were identified using a validated algorithm and classified based on recent (<3 years) or former (≥3 years before SVR) use. Crude reinfection rates per 100 person-years (PYs) were …
学术搜索中的文章
C Rossi, ZA Butt, S Wong, JA Buxton, N Islam, A Yu… - Journal of hepatology, 2018